Show simple item record

dc.contributor.authorDrilon, A
dc.contributor.authorBarlesi, F
dc.contributor.authorDe Braud, F
dc.contributor.authorCho, BC
dc.contributor.authorAhn, MJ
dc.contributor.authorSiena, S
dc.contributor.authorKrebs, Matthew G
dc.contributor.authorLin, CC
dc.contributor.authorJohn, T
dc.contributor.authorTan, DSW
dc.contributor.authorSeto, T
dc.contributor.authorDziadziuszko, R
dc.contributor.authorArkenau, HT
dc.contributor.authorRolfo, C
dc.contributor.authorWolf, J
dc.contributor.authorYe, C
dc.contributor.authorRiehl, T
dc.contributor.authorEng, S
dc.contributor.authorDoebele, RC
dc.date.accessioned2019-11-19T16:01:01Z
dc.date.available2019-11-19T16:01:01Z
dc.date.issued2019en
dc.identifier.citationDrilon A, Barlesi F, De Braud F, Cho B, Ahn M, Siena S, et al. Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2. Cancer Res. 2019;79(13).en
dc.identifier.doi10.1158/1538-7445.AM2019-CT192en
dc.identifier.urihttp://hdl.handle.net/10541/622423
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1158/1538-7445.AM2019-CT192en
dc.titleEntrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentThoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York,en
dc.identifier.journalCancer Researchen


This item appears in the following Collection(s)

Show simple item record